C. R. BARD, INC. (NYSE:BCR) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On December22, 2016, the Board of Directors of C. R. Bard, Inc.
(the Company) amended the Companys By-Laws (the Amended and
Restated By-laws), effective as of December22, 2016, to implement
proxy access.
Article IV, Section4 of the Amended and Restated By-Laws permits
a stockholder, or a group of up to 20 stockholders, owning at
least 3% of the Companys outstanding common stock continuously
for at least three years to nominate and include in the Companys
proxy materials director nominees constituting up to the greater
of two individuals or 20% of the number of directors currently
serving on the Companys Board of Directors, provided that the
stockholders and the nominees satisfy the requirements specified
in, and otherwise comply with the provisions of, the Amended and
Restated By-laws.
The description set forth above regarding the Companys Amended
and Restated By-Laws is qualified in its entirety by reference to
the full text of the Companys Amended and Restated By-Laws, a
copy of which is filed as Exhibit 3.1 to this Current Report on
Form 8-K and incorporated herein by reference.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 3.1 |
Amended and Restated By-Laws of C. R. Bard, Inc., effective as of December22, 2016 |
About C. R. BARD, INC. (NYSE:BCR)
C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. It operates through the manufacturing and sale of medical devices segment. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease (PVD), end-stage renal disease (ESRD) and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted grafts and fixation devices for hernia and soft tissue repairs. C. R. BARD, INC. (NYSE:BCR) Recent Trading Information
C. R. BARD, INC. (NYSE:BCR) closed its last trading session up +2.42 at 223.10 with 318,807 shares trading hands.
